Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma

<p>Cluster defining genes from scRNAseq data</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Isha Mondal (16721699) (author)
Kolejni autorzy:	Oishika Das (16721702) (author), Raymond Sun (16721705) (author), Jian Gao (16721708) (author), Bohyeon Yu (16721711) (author), Aaron Diaz (16721714) (author), Jinan Behnan (16721717) (author), Abhishek Dubey (16721720) (author), Zhipeng Meng (16721723) (author), Emad Eskandar (16721726) (author), Beisi Xu (14941098) (author), Rongze Olivia Lu (16721729) (author), Winson S. Ho (16721732) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Tumor Biology Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Immune responses to cancer Immunotherapy Combination immunotherapy Tumor Microenvironment Immune cells and the microenvironment
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Wydane: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Wydane: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Wydane: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Wydane: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
od: Francisco Hermida-Prado (14958909)
Wydane: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Wydane: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Wydane: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Wydane: (2025)

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
od: Axel Stenmark Tullberg (15029928)
Wydane: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
od: Andrew Nguyen (17142197)
Wydane: (2025)

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
od: Kankan Cao (16437263)
Wydane: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
od: Carlotta Antoniotti (15352506)
Wydane: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
od: Carlotta Antoniotti (15352506)
Wydane: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
od: Carlotta Antoniotti (15352506)
Wydane: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Wydane: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Wydane: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Wydane: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Wydane: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Wydane: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
od: Clare Vesely (505402)
Wydane: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
od: Erika Y. Faraoni (14844897)
Wydane: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
od: Erika Y. Faraoni (14844897)
Wydane: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
od: Erika Y. Faraoni (14844897)
Wydane: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
od: Maria Lozano-Rabella (15056515)
Wydane: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
od: Maria Lozano-Rabella (15056515)
Wydane: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
od: Maria Lozano-Rabella (15056515)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_4v7uvlffje57emh33hj5u9jr6c